Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard Ultra Short Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.94 (market cap $39.89B), while Vanguard Ultra Short Bond ETF trades at $49.65. Which is the better fit depends on your goals.
| ALNY | VUSB | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $50.03 |
52-Week Low | $278.09 | $49.60 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VUSB trades at $49.66 with minimal daily movement, showing a slight 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators are neutral. The ETF offers a yield of approximately 4.35% and is positioned as a cash alternative amid a non-inverted yield curve, with recent dividends paid in mid-2026.
The outlook for VUSB is cautious due to bearish technicals and potential Fed rate increases in 2026, which could impact short-term bonds. Risks include interest rate sensitivity and credit/duration exposure, but the ETF remains a viable option for investors seeking yield above money-market funds with moderate risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
